Open AccessThe role of phenofibrate in the treatment of microvascular complications of type 2 diabetes mellitus
Author(s) -
Larisa Viktorovna Koshel,
Т. И. Романцова
Publication year - 2009
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-5714
Subject(s) - medicine , inflammation , endocrinology , fibrinogen , type 2 diabetes mellitus , receptor , diabetes mellitus , c reactive protein , type 2 diabetes
Results of numerous studies give definitive evidence that phenofibrate affects activity of PPAR-a receptors in liver and thereby decreases the level oflipids responsible for the development of atherosclerosis (VLDL, small dense LDL); simultaneously, it increases the level of anti-atherogenic HDL.Activation of PPAR-a receptors in vascular cells decreases activity of inflammation markers, such as C-reactive protein, TNF-a, IL-6, fibrinogen,etc. These effects of phenofibrate eventually lead to reduced risk of macro- and microvascular diabetic complications.